T1	Participants 78 132	yperphosphatemic patients with end-stage renal disease
T2	Participants 193 241	patients receiving long-term dialysis treatment.
T3	Participants 585 611	Chinese patients with ESRD
T4	Participants 377 421	patients with end-stage renal disease (ESRD)
